Camurus AB
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Sven Fredrik Tiberg
- Full Time Employees
- 285
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Rydbergs torg 4 Lund SN Sweden 224 84
- IPO Date
- Dec 3, 2015
- Website
- camurus.com
- Similar Companies
- Business
- Camurus AB (publ) (Nasdaq Stockholm: CAMX) develops and commercializes innovative, long-acting medicines based on its proprietary FluidCrystal technology for patients with severe and chronic diseases in areas including opioid dependence, acromegaly, pain, cancer, endocrine disorders, and metabolic conditions; core products comprise Buvidal, a weekly and monthly buprenorphine prolonged-release injection for opioid dependence treatment in adults and adolescents aged 16 and over in Europe, Australia, and MENA regions, and Brixadi, the US brand licensed to Braeburn Pharmaceuticals for the same indication; the pipeline features Oczyesa (CAM2029), a once-monthly subcutaneous octreotide depot approved in the EU and UK for acromegaly and launched in Germany with further European roll-outs planned and US approval targeted for Oclaiz in 2026, alongside candidates such as CAM2029 for gastroenteropancreatic neuroendocrine tumors (Phase 3 SORENTO ongoing) and polycystic liver disease, CAM2056 (monthly semaglutide depot with topline Phase 1b results expected November 2025), CAM4072 for genetic obesity disorders licensed to Rhythm Pharmaceuticals, CAM2038 for chronic pain, CAM4071 for endocrine disorders, CAM2043 for Raynaud's phenomenon and pulmonary arterial hypertension, and others in oncology and supportive care. Founded in 1991 and headquartered in Lund, Sweden, with over 275 employees and regional offices in Cambridge (UK), Mainz (Germany), Sydney (Australia), and Princeton (New Jersey, US), the company operates across Europe, the US, Australia, and MENA, targeting healthcare providers, patients with opioid use disorder, acromegaly, neuroendocrine tumors, and related chronic conditions. Recent developments include a June 2025 collaboration and license agreement with Eli Lilly granting worldwide rights for long-acting FluidCrystal-based incretin products targeting dual GIP/GLP-1, triple GIP/glucagon/GLP-1, and amylin receptor agonists for cardio-metabolic health initiated in Q3 2025; UK MHRA approval of Oczyesa for acromegaly in August 2025 and FDA/European Commission orphan drug designations for CAM2029 in autosomal dominant polycystic kidney disease; talks reported in September 2025 to acquire US-based Braeburn Pharmaceuticals in a potential $1 billion deal to bolster direct control of Brixadi US sales; appointment of Anders Vadsholt as CFO; and updated 2025 financial guidance lowering total revenues to SEK 2.3-2.6 billion while maintaining profit before tax at SEK 0.9-1.2 billion, reflecting Q3 net sales growth and robust cash position of SEK 3.5 billion.
Company News
Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA
Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA
Camurus AB (publ) (CAMRF) Q2 2026 Earnings Call Transcript
Camurus' hormone disorder drug expected to be approved in 2027 after fresh FDA setback
Camurus announces expansion of Lilly collaboration
Camurus announces expansion of Lilly collaboration
Camurus AB (publ) (CAMRF) Q1 2026 Earnings Call Transcript
Camurus AB (publ) (CAMRF) Q4 2025 Earnings Call Transcript
Camurus AB (publ) (CAMRF) Q3 2025 Earnings Call Transcript
Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins
US FDA declines to approve Camurus' rare hormone disorder drug
New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl